Behnava Bita, Sharafi Heidar, Keshvari Maryam, Pouryasin Ali, Mehrnoush Leila, Salimi Shima, Karimi Elizee Pegah, Ghazimoghaddam Mehran, Alavian Seyed Moayed
Iran Hepatitis Network, Tehran, IR Iran; Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran.
Iran Hepatitis Network, Tehran, IR Iran; Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran; Armin Pathobiology Laboratory, Tehran, IR Iran.
Hepat Mon. 2016 Jan 23;16(1):e32703. doi: 10.5812/hepatmon.32703. eCollection 2016 Jan.
Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients. In these patients, iron overload and their comorbidities make difficulties during Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV) therapy.
We aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV.
This cross - sectional study was conducted on 143 thalassemic patients with chronic hepatitis C, who were treated with a combination of PEG-IFN and RBV regimen. The rs12979860 and rs8099917 polymorphisms were assessed as the most common polymorphisms near the IL28B gene by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
The rate of sustained virological response (SVR) was significantly lower in thalassemic patients with HCV genotype-1 infection compared to patients with HCV genotype-3 infection. Among baseline predictors, rs12979860 and rs8099917 polymorphisms were found to be the only parameters associated with achievement of SVR in thalassemic patients with HCV genotype-1 infection however, there was no association between these polymorphisms and the rate of SVR in thalassemic patients with HCV genotype-3 infection.
In HCV genotype-1- infected thalassemic patients with rs12979860 CC genotype and without severe comorbidities, PEG-IFN and RBV combination therapy can be tried yet in those with rs12979860 CT/TT it may be reasonable to treat cases with new direct-acting antivirals.
丙型肝炎病毒（HCV）是地中海贫血患者肝衰竭的主要原因。在这些患者中，铁过载及其合并症给聚乙二醇干扰素（PEG-IFN）和利巴韦林（RBV）治疗带来困难。
我们旨在评估IL28B基因附近多态性对接受PEG-IFN和RBV治疗的HCV感染地中海贫血患者病毒学应答的影响。
本横断面研究对143例慢性丙型肝炎地中海贫血患者进行，这些患者接受了PEG-IFN和RBV联合治疗方案。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法评估rs12979860和rs8099917多态性，将其作为IL28B基因附近最常见的多态性。
与HCV基因3型感染患者相比，HCV基因1型感染的地中海贫血患者持续病毒学应答（SVR）率显著更低。在基线预测因素中，rs12979860和rs8099917多态性被发现是与HCV基因1型感染的地中海贫血患者实现SVR相关的唯一参数，然而，这些多态性与HCV基因3型感染的地中海贫血患者的SVR率之间没有关联。
在HCV基因1型感染且rs12979860为CC基因型且无严重合并症的地中海贫血患者中，可以尝试PEG-IFN和RBV联合治疗，但对于rs12979860为CT/TT基因型的患者，使用新型直接作用抗病毒药物治疗可能是合理的。
